Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | RXRA | P19793 | 2/20 | 0.53 |
| ▸ | RXRB | P28702 | 2/20 | 0.53 |
| ▸ | RXRG | P48443 | 2/20 | 0.53 |
| ▸ | MALT1 | Q9UDY8 | 16/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9520169 | 0.80 | RXRA (0.56) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL5387633 | 0.79 | PTGS2 (0.69) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL6309492 | 0.75 | PTGS2 (0.66) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL9520300 | 0.75 | ALOX5 (0.79) | PTGS2ALOX5RXRARXRBRXRG | |
| Tepoxalin SCHEMBL75441 | 0.75 | PTGS2 (1.00) | PTGS2ALOX5RXRARXRBRXRG | |
| Tepoxalin SCHEMBL9519652 | 0.74 | PTGS2 (0.98) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL6310403 | 0.73 | PTGS2 (0.74) | PTGS2ALOX5 | |
| SCHEMBL9519402 | 0.73 | PTGS2 (0.71) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL9080028 | 0.72 | PTGS2 (0.81) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL9522439 | 0.71 | PTGS2 (0.79) | PTGS2ALOX5RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-15 | — | — | US | claimed |
| EP-1675585-A2 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | TANABE SEIYAKU CO., LTD. (JP) | 2006-07-05 | — | — | EP | claimed |
| WO-2005037271-A2 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | TANABE SEIYAKU CO., LTD. (JP) | 2005-04-28 | — | — | WO | claimed |
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1675585-A2 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | TANABE SEIYAKU CO., LTD. (JP) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037271-A2 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | TANABE SEIYAKU CO., LTD. (JP) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | KCNN3, KCNN1, KCNN2 | PTGS2 594/4885ALOX5 1143/4885RXRA 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.